Original post: HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma
Original post: HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma
See original here: FDA Approves New Prostate Cancer Imaging Agent Gozellix®
More: UNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE Study of UBX1325 in Patients with Diabetic...
Read more from the original source: 23andMe Initiates Voluntary Chapter 11 Process to Maximize Stakeholder Value Through Court-Supervised Sale Process
Read this article: Junshi Biosciences Announces Approval of sNDA for Toripalimab in Combination with Bevacizumab for 1st-line Treatment of Advanced Hepatocellular...
More: Opthea Announces COAST Phase 3 Trial Topline Results
Read more from the original source: Santhera to share latest on commercial rollout of AGAMREE® and future strategic priorities at Capital Markets Day
Go here to read the rest: DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the...
Follow this link: Press Release: Availability of the Q1 2025 Aide mémoire
See the rest here: Abivax Announces Full Year 2024 Financial Results
Recent Comments